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ABSTRACT 
Objective 
The effectiveness of anakinra (interleukin-1 receptor antagonist) in early rheumatoid arthritis 
(RA) is unknown. We evaluated the efficacy of anakinra (combined with methotrexate) in a 
randomised clinical trial of early active RA patients. 
 
Methods 
The Combination Anti-Rheumatic Drugs in Early RA-2 (CARDERA-2) trial was a 
randomised trial of early (duration <1 year) active RA. Patients were randomised to 12-
months of: (1) methotrexate or (2) anakinra-methotrexate. Follow-up lasted 2 years. The 
primary outcome was erosive progression (changes from baseline in modified Larsen scores). 
Secondary outcomes were changes from baseline in disease activity score on a 28-joint count 
(DAS28), health assessment questionnaire (HAQ), and quality of life (EQ-5D) scores 
alongside ACR responder rates. 
 
Results 
154 patients received the allocated intervention (from 259 screened). Similar Larsen score 
progression was seen at 12 and 24-months in patients receiving anakinra-methotrexate (mean 
changes from baseline of 2.50 and 5.10, respectively) and methotrexate monotherapy (mean 
changes from baseline of 4.16 and 5.20, respectively). Lower improvements in DAS28 and 
HAQ scores were seen at all time-points in anakinra-methotrexate treated patients; these were 
significantly less at 24-months (DAS28 P=0.04; HAQ P=0.02). Significantly lower EQ-5D 
score increases were seen at 12-months with anakinra-methotrexate (P=0.03). Anakinra-
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methotrexate was associated with more serious adverse events (11 vs. 6 patients) and 
toxicity-related withdrawals (10 vs. 2 patients) compared with methotrexate. 
 
Conclusion 
Anakinra (combined with methotrexate) is not effective in early, active RA. It provided no 
clinical benefits beyond methotrexate monotherapy and had more serious adverse events. 
 
MeSH Indexing Terms 
Arthritis, Rheumatoid; Interleukin 1 Receptor Antagonist Protein; Clinical Trial. 
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INTRODUCTION 
Current rheumatoid arthritis (RA) management focuses on early intensive treatment with 
disease-modifying anti-rheumatic drugs (DMARDs) escalated to biologics in refractory cases 
[1]. First-line biologics like tumour necrosis factor (TNF)-inhibitors are effective in early and 
established RA [2]. Anakinra, an interleukin-1 receptor antagonist (IL-1ra), is approved for 
DMARD refractory moderate-severe RA [3] . Its efficacy in established RA is less than TNF-
inhibitors [4]; consequently it is infrequently used in RA management. Its efficacy in early 
RA is unknown.  
 
Treatments are usually most effective if instituted promptly after RA onset [5]. We therefore 
evaluated the efficacy of anakinra in a randomised clinical trial of early active RA patients. 
Our primary hypothesis was that in early active RA, anakinra-methotrexate combination 
therapy is superior to methotrexate monotherapy in reducing erosive progression. 
 
MATERIALS AND METHODS 
Trial design 
The Combination Anti-Rheumatic Drugs in Early RA-2 (CARDERA-2) trial was an open-
label, multicentre, two-armed trial. Patients were randomised equally to methotrexate 
monotherapy or anakinra-methotrexate combination therapy. Active treatment was given for 
12-months; follow-up lasted 24-months. 
 
Centres 
Routine rheumatology clinics at 11 English centres. 
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Inclusion/Exclusion Criteria 
Included patients met the 1987 American College of Rheumatology (ACR) classification 
criteria, had early (duration <12 months), active disease (three from: ≥3 swollen joints, ≥6 
tender joints, ≥45 minutes morning stiffness, erythrocyte sedimentation rate (ESR) 
≥28mm/hr), were aged ≥18 years and could give informed consent. 
 
Excluded patients had other inflammatory arthropathies, previous methotrexate treatment, 
contraindications/intolerance to the trial drugs, other serious medical disorders or were using 
oral steroids. 
 
Interventions 
Open-label methotrexate started at 7.5mg/week, and increased two weekly by 2.5mg to 
15mg/week. Further increases to 25mg/week occurred if clinically needed. Other DMARD 
monotherapies were started for significant side-effects or inadequate responses. 
 
Open-label anakinra (100mg/day by subcutaneous injection) was given with methotrexate (as 
outlined above). 
 
Study treatments were given for 12-months. Subsequent treatment was decided by patients’ 
rheumatologists. 
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Outcomes 
Primary Outcome 
Erosive progression, as captured by changes from baseline in modified Larsen scores. 
 
Secondary Outcomes 
Changes from baseline in disease activity score for 28-joint counts (DAS28), health 
assessment questionnaire (HAQ) and quality of life (EQ-5D) scores alongside ACR-20, 50 
and 70 responder rates. 
 
Assessments 
Hand and feet X-rays were taken at 0, 12 and 24-months. Other outcomes were additionally 
assessed at 6-months. Assessors were independent to the supervising clinician and blinded to 
treatment. Radiographs were read chronologically by one rheumatologist (DLS) experienced 
in radiological scoring, blinded to treatment. 
 
Adverse Events 
These were captured, irrespective of their relation to treatment. 
 
Sample Size 
CARDERA-2 tested the hypothesis that anakinra-methotrexate would reduce the number of 
patients developing new erosions by 40% over 12-months compared with methotrexate 
monotherapy. Existing data suggested 71% of patients receiving methotrexate would develop 
new erosions over 12-months. Showing a 40% reduction with 5% significance and 90% 
7 
 
power required 66 patients per group. Allowing for 20% dropouts the sample size was 158 
patients. 
 
Randomisation 
Patients were randomly allocated to one group. The trial statistician generated the allocation 
sequence using random number tables. Randomisation (stratified by region) used 6 random 
treatment assignments in blocks of 4. Randomisation numbers were assigned chronologically 
at screening visits. Metrologists and the trial co-ordinator were unaware of the allocation 
sequence. Treatment assignments were in a locked cabinet in the co-ordinating centre 
pharmacy for emergency access. 
 
Statistical Analysis 
Intention-to-treat (ITT) analyses evaluated treatment effects on changes from baseline in 
Larsen scores (primary outcome) and DAS28, HAQ and EQ-5D scores (secondary outcomes) 
at 12 and 24-months using linear regression. Univariate analyses used relevant outcomes as 
response variables and treatment as the explanatory variable. Multivariate analyses added 
demographic variables (gender, age, ethnicity, disease duration) as covariates.  Robust 
standard errors (SE) were used.  ACR responder rates were evaluated using logistic 
regression, accounting for demographic variables. Statistical significance was 5% using a 2-
sided P-value. As 12-month Larsen scores were only missing in 9 patients (3 methotrexate; 6 
anakinra-methotrexate) and DAS28/HAQ/EQ-5D in 4 patients (1 methotrexate; 3 anakinra-
methotrexate) missing data were not imputed. Data management and analyses were 
performed using Stata, version 12.0 (Stata Corp, College Station, TX). 
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Ethical Review  
CARDERA-2 was approved by the South East Research Ethics Committee (REC reference 
number MREC 02/1/089). All participants provided informed consent.  
 
RESULTS 
Participants 
259 patients were screened (Figure 1): 100 were excluded (37 ineligible; 59 declined); 159 
were randomised to treatment; 154 received the allocated intervention. 
 
Baseline Characteristics 
These were similar between groups (Table 1). Baseline radiological damage was greater in 
the anakinra-methotrexate group (mean Larsen scores 15.3 vs. 7.0).  
 
Patients Analysed 
Of the 154 patients receiving treatment (Figure 1), 118 (77%) continued therapy for 12-
months (20 discontinued treatment; 5 lost to follow-up). 12 and 24-month data were available 
for Larsen scores in 145 (94%) and 130 (84%) patients, respectively and for DAS28, HAQ, 
and EQ-5D scores in 150 (97%) and 131 (85%) patients, respectively.  
 
Primary Outcome 
Lower Larsen score increases were seen at 12 and 24-months with anakinra-methotrexate 
(Figure 2; mean change from baseline of 2.50 and 5.10) compared with methotrexate 
monotherapy (mean change from baseline of 4.16 and 5.20). These differences between 
groups were not significant (Table 2). 
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Secondary Outcomes 
DAS28 
Greater DAS28 reductions were seen at 12 and 24-months with methotrexate monotherapy 
(Figure 2; mean change from baseline of -2.22 and -2.42) compared with anakinra-
methotrexate (mean change from baseline of -2.10 and -1.80). This was significant at 24-
months (Table 2; adjusted model P=0.04). 
 
HAQ 
Greater HAQ score reductions were seen at 12 and 24-months with methotrexate 
monotherapy (Figure 2; mean change from baseline of -0.45 and -0.48) compared with 
anakinra-methotrexate (mean change from baseline of -0.37 and -0.25). This was significant 
at 24-months (Table 2; adjusted model P=0.02). 
 
EQ-5D 
Greater EQ-5D score improvements were seen at 12 and 24-months with methotrexate 
monotherapy (Figure 2; mean change from baseline of 0.21 and 0.20) compared with 
anakinra-methotrexate (mean change from baseline of 0.11 and 0.15). This was significant at 
12-months (Table 2; adjusted model P=0.03). 
 
ACR Responder Rates 
At 12-months more patients attained an ACR20 and ACR50 response with anakinra-
methotrexate compared with methotrexate monotherapy; the opposite was seen for ACR70 
responses. None of these differences were significant (Table 2). 
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At 24-months more patients attained ACR20, ACR50 and ACR70 responses with 
methotrexate monotherapy. A significant difference was seen for ACR20 response rates; the 
adjusted OR for attaining an ACR20 response with anakinra-methotrexate compared with 
methotrexate was 0.44 (95% CI 0.21-0.93; P=0.03).  
 
Adverse Events 
136 adverse events occurred. More occurred with anakinra-methotrexate than with 
methotrexate monotherapy (70 vs. 66), although this was not significant (fisher’s exact test 
P=0.99). More serious adverse events occurred with anakinra-methotrexate than with 
methotrexate monotherapy (11 vs. 6). 
 
Withdrawals 
Significantly more withdrawals were seen (chi-square test P=0.007) with anakinra-
methotrexate than with methotrexate monotherapy (Figure 1; 19 vs. 6 patients).  This 
difference was mainly due to toxicity; 2 and 10 patients withdrew from receiving 
methotrexate monotherapy and anakinra-methotrexate, respectively due to toxicity. 
 
DISCUSSION 
CARDERA-2 shows anakinra combined with methotrexate is not effective in early, active 
RA. It had no benefits beyond methotrexate monotherapy on erosive progression, disability, 
disease activity or quality of life. It gave more serious adverse events and was more 
frequently discontinued due to adverse effects. After 24-months, patients who had received 
anakinra-methotrexate had significantly more active disease and disability than patients 
receiving methotrexate monotherapy. 
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The inefficacy of IL-1 inhibition in early RA was disappointing. There is strong evidence that 
IL-1 is a pivotal cytokine in established RA. In such patients the IL-1β isoform is abundant in 
plasma [6] and synovial fluid [7] (compared with controls) and serum levels correlate with 
disease severity [6]. IL-1 inhibition significantly reduces joint destruction in mouse models 
[8] and established RA patients [9]; it also effectively reduces disease activity in established 
RA [4]. Our findings suggest biologic pathways governing RA activity may differ between 
early and established disease.  The apparent worsening of clinical outcomes after 24-months 
in patients receiving anakinra was unexpected. As it is unlikely that anakinra will be used in 
this setting, the underlying reasons for this worsening are of no practical clinical consequence 
and remain unexplained. 
 
Our study has several strengths. The randomisation process was rigorous, outcomes were 
evaluated by assessors blinded to patient treatment, multiple centres were involved and an 
ITT analysis was used. It has several limitations. Patients were un-blinded because injection 
site reactions with anakinra make full blinding impractical. Some data were missing, albeit at 
low levels. As with other contemporary early RA cohorts, erosive progression was low (only 
26% had a minimal clinically important annual increase in Larsen scores of ≥2.3 units over 
the first 12-months [10]), reducing the power to detect treatment effects on erosive 
progression. 
 
In conclusion, anakinra is ineffective in early active RA. Our findings support the National 
Institute for Health and Care Excellence’s (NICE) decision to not recommend its use in RA 
management [11]. 
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Table 1. Baseline Patient Characteristics by Treatment Group 
Patient Characteristic Methotrexate Monotherapy Anakinra-Methotrexate 
 (N=75) (N=79) 
Mean Age in Years (SD) 54 (13) 56 (12) 
Female, n (%) 54 (72) 54 (68) 
Caucasian, n (%) 67 (89) 65 (82) 
Mean Disease Duration, Months (SD) 0.14 (0.19) 0.13 (0.15) 
Mean Larsen (SD) 7.0 (10.5) 15.3 (18.7) 
RF-Positive, n (%) 54 (72) 53 (67.1) 
Mean DAS28 (SD) 6.45 (1.22) 6.37 (1.19) 
Mean HAQ (SD) 1.58 (0.79) 1.49 (0.71) 
Mean EQ-5D (SD) 0.39 (0.34) 0.40 (0.34) 
 
n = number; SD = standard deviation; RF= Rheumatoid Factor; DAS28 = Disease Activity 
Score on a 28-joint count; HAQ = Health Assessment Questionnaire
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Table 2. Regression Models Showing the Effect of Anakinra on Disease Outcomes 
Outcome 
Model 1 (Unadjusted) Model 2 (Adjusted)* 
12-months 24-months 12-months 24-months 
Linear Regression 
 β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value 
Larsen -1.70 (-4.73, 1.34) 0.27 -0.10 (-3.27, 3.07) 0.95 -1.88 (-5.33, 1.58) 0.29 -0.05 (-3.08, 2.99) 0.98 
HAQ 0.08 (-0.15, 0.32) 0.49 0.23 (-0.02, 0.48) 0.07 0.12 (-0.11, 0.36) 0.29 0.28 (0.04, 0.52) 0.02 
EQ-5D -0.09 (-0.21, 0.02) 0.09 -0.04 (-0.17, 0.08) 0.48 -0.12 (-0.23, -0.01) 0.03 -0.07 (-0.19, 0.05) 0.25 
DAS28 0.16 (-0.45, 0.78) 0.60 0.62 (-0.10, 1.35) 0.09 0.29 (-0.31, 0.89) 0.34 0.73 (0.03, 1.44) 0.04 
Logistic Regression 
 OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
ACR20 1.28 (0.67, 2.45) 0.46 0.50 (0.25, 1.02) 0.06 1.23 (0.63, 2.43) 0.55 0.44 (0.21, 0.93) 0.03 
ACR50 1.13 (0.54, 2.33) 0.75 0.63 (0.28, 1.42) 0.26 1.07 (0.60, 2.27) 0.86 0.55 (0.22, 1.33) 0.18 
ACR70 0.72 (0.29, 1.77) 0.48 0.68 (0.21, 2.27) 0.53 0.69 (0.26, 1.82) 0.45 0.65 (0.18, 2.38) 0.51 
 
* Model 2 includes following covariates: age, gender, ethnicity, disease duration; methotrexate monotherapy used as reference group in linear 
and logistic regression models. 
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Figure 1. Consort Flowchart for CARDERA-2 
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Figure 2. Treatment Effect on Larsen, DAS28, HAQ and EQ-5D Scores 
 
 
Mean change from baseline with standard error bars shown at each time point for each 
outcome; *=denotes significant difference between treatment arms at  
 P<0.05 (from adjusted linear regression model). 
 
